Drug Trial Radar · NCT07083154
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Sep 27, 2025
Primary completion
Aug 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nanjing First Hospital, Nanjing Medical University; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Xiangya Hospital of Central South University; Huadong Hospital; Jiangsu Province Hospital of Traditional Chinese Medicine; Changzhou No.2 People's Hospital; The Second Affiliated Hospital of Dalian Medical University
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and early-stage cognitive impairment, defined as mild cognitive impairment (MCI) or mild dementia. Participants are randomized 1:1 to receive once-weekly subcutaneous mazdutide, with dose escalation according to the protocol, or matching placebo, in addition to background glucose-lowering therapy. The primary objective is to determine whether 76 weeks of mazdutide treatment can slow cognitive and functional decline compared with placebo in this population.
Conditions
- Dementia, Mild
- Mild Cognitive Impairment
- Type 2 Diabetes
Interventions
MazdutideDrug
Mazdutide is administered once weekly by subcutaneous injection using a prefilled autoinjector pen, preferably on the same day each week. Treatment is initiated at 2.0 mg once weekly and up-titrated to 4.0 mg once weekly during Weeks 4-12 according to individual tolerability. After at least 4 weeks at 4.0 mg, further escalation to 6.0 mg once weekly may be considered if prespecified criteria are met. Participants who are unable to tolerate a given dose may continue treatment at the highest tolerated dose. The total treatment duration is 76 weeks.
PlaceboDrug
Matching placebo is administered once weekly by subcutaneous injection using a prefilled autoinjector pen. Participants will undergo the same blinded titration and dose-adjustment schedule as the mazdutide group, including corresponding 2.0 mg, 4.0 mg, and, where applicable, 6.0 mg dosing levels. Participants unable to tolerate a given dosing level may remain at the highest tolerated level. The total treatment duration is 76 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Integrated Alzheimer's Disease Rating Scale (iADRS) Score ChangeTime frame: From Baseline to Week 76
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Department of Endocrinology, Huadong Hospital Affiliated to Fudan University
Shanghai, China · Recruiting
Department of Endocrinology, Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Department of Endocrinology, Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China · Recruiting
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Nanjing, Jiangsu, China · Recruiting
Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Not yet recruiting
Department of Endocrinology, Shanghai General Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.